(Q37196395)

18 August 2017

1 reference

title

Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis (English)

1 reference

18 August 2017

2

Amylou Dueck

1 reference

18 August 2017

1

Vera J Suman

1 reference

18 August 2017

Daniel J Sargent

3

1 reference

18 August 2017

language of work or name

1 reference

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

26

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

439-444

1 reference

18 August 2017

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Design of phase I and II clinical trials in cancer: a statistician's view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Design and analysis of phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

A comparison of two phase I trial designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

The continual reassessment method in cancer phase I clinical trials: a simulation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Some practical improvements in the continual reassessment method for phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Clinical trial designs for cytostatic agents: are new approaches needed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Targeted antitumour therapy--future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Clinical trial designs for targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Dose-finding based on efficacy-toxicity trade-offs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

An adaptive dose-finding design incorporating both toxicity and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Application of a new multinomial phase II stopping rule using response and early progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Multinomial phase II cancer trials incorporating response and early progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Calibrated phase II clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Design issues of randomized phase II trials and a proposal for phase II screening trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

A flexible design for multiple armed screening trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

A two-stage design for choosing among several experimental treatments and a control in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Challenges in breast cancer clinical trial design in the postgenomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

Clinical trial designs for predictive marker validation in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971057

10.1080/07357900801971057

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference